



## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 05 June 2020.

I am pleased to confirm the following.

## Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

Afatinib - 5 Atezolizumab monotherapy or combination - 2 Brigatinib - 0 Ceretinib - 0 Crizotinib - 2 **Docetaxel mono or combination - 3** Erlotinib - 0 Gefitinib - 0 Gemcitabine - 1 Nitendanib + docetaxel - 0 Nivolumab - 0 **Osimertinib** - 1 Paclitaxel - 3 Pembrolizumab - 31 **Pembrolizumab chemo in combination - 9** Pembrolizumab monotherapy - 22 Pemetrexed monotherapy of combination with Carboplatin/Cisplatin - 1 Ramucirumab - 0 Vinorelbine mono or combination - 1 Other active systemic anti-cancer therapy Palliative care only

Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?

Afatinib

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns. Chief Executive: Joe Harrison Chairman: Simon Lloyd

Atezolizumab monotherapy or combination Brigatinib Ceretinib Crizotinib Docetaxel mono or combination Erlotinib Gefitinib Gemcitabine Nitendanib + docetaxel Nivolumab Osimertinib Paclitaxel Pembrolizumab monotherapy Pembrolizumab chemo in combination Pembrolizumab monotherapy Pemetrexed monotherapy of combination with Carboplatin/Cisplatin Ramucirumab Vinorelbine mono or combination Other active systemic anti-cancer therapy Palliative care only

Please see attachment for answers to question 2.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

> Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.